The ABIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ABIO Detailed Price Forecast - CNN Money||View ABIO Detailed Summary - Google Finance|
|View ABIO Detailed Summary - Yahoo! Finance||View ABIO Stock Research & Analysis - Zacks.com|
|View ABIO Trends & Analysis - Trade-Ideas||View ABIO Major Holders - Barrons|
|View ABIO Call Transcripts - NASDAQ||View ABIO Breaking News & Analysis - Seeking Alpha|
|View ABIO Annual Report - CompanySpotlight.com||View ABIO OTC Short Report - OTCShortReport.com|
|View ABIO Fundamentals - TradeKing||View ABIO SEC Filings - Bar Chart|
|View Historical Prices for ABIO - The WSJ||View Performance/Total Return for ABIO - Morningstar|
|View the Analyst Estimates for ABIO - MarketWatch||View the Earnings History for ABIO - CNBC|
|View the ABIO Earnings - StockMarketWatch||View ABIO Buy or Sell Recommendations - MacroAxis|
|View the ABIO Bullish Patterns - American Bulls||View ABIO Short Pain Metrics - ShortPainBot.com|
|View ABIO Stock Mentions - StockTwits||View ABIO Stock Mentions - PennyStockTweets|
|View ABIO Stock Mentions - Twitter||View ABIO Investment Forum News - Investor Hub|
|View ABIO Stock Mentions - Yahoo! Message Board||View ABIO Stock Mentions - Seeking Alpha|
|View Insider Transactions for ABIO - SECform4.com||View Insider Transactions for ABIO - Insider Cow|
|View ABIO Major Holdings Summary - CNBC||View Insider Disclosure for ABIO - OTC Markets|
|View Insider Transactions for ABIO - Yahoo! Finance||View Institutional Holdings for ABIO - NASDAQ|
|View ABIO Stock Insight & Charts - FinViz.com||View ABIO Investment Charts - StockCharts.com|
|View ABIO Stock Overview & Charts - BarChart||View ABIO User Generated Charts - Trading View|
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Posted on Wednesday August 21, 2019
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. (“Abiomed” or “the Company”) (NASDAQ: ABMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Posted on Thursday August 01, 2019
FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction.
One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price
Posted on Tuesday June 04, 2019
If you're interested in ARCA biopharma, Inc. (NASDAQ:ABIO), then you might want to consider its beta (a measure of...
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced it recently filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering Gencaro’s (bucindolol hydrochloride) potential treatment effect in preventing atrial fibrillation (AF) in patients with heart failure (HF). The patent application is based on recent novel findings from the GENETIC-AF Phase 2B study of Gencaro, described in “GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population,” published in JACC: Heart Failure, a journal of the American College of Cardiology.